Quality of Life following Allogeneic Stem Cell Transplantation for patients over 60 years with Acute Myeloid Leukaemia

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020
Full text from:
Abstract
This study of patients with acute myeloid leukemia (AML) aged ≥ 60 years analysed the association between patients' performance indices; haematopoietic stem cell transplantation comorbidity index (HCT-CI), Karnofsky Performance Score (KPS) and European Society for Blood and Marrow Transplantation (EBMT) risk score prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) and quality of life (QoL), quantified using the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT), in the first year post allo-HSCT. Over 7 years, 48 evaluable patients underwent reduced intensity conditioning (RIC) allo-HSCT. Median age was 65 years (range 60-74), with 2 year and 5 year overall survival (OS) of 65.8% and 52.3% respectively. A significant improvement across all QoL scores was observed over the 12 months post-HSCT. HCT-CI 0 was associated with improved general QoL (FACT-G) score at 6 months when compared with patients with HCT-CI 1-2 (p=0.032). At 12 months post-HSCT a higher HCT-CI ≥ 3 pre-transplant correlated with lower QoL scores across the domains (symptom related QoL (FACT-TOI), p=0.036; FACT-G, p=0.05; BMT-related QoL (FACT-BMT), p=0.036). Pre-transplant KPS 100 v 80-90 predicted for improved QoL at 6 months (FACT-TOI, p=0.009), FACT-G, p=0.001, FACT-BMT, p=0.002) but was not observed at one year post-HSCT. We demonstrate that KPS and HCT-CI can predict QoL in the early post-transplant period with a favourable overall survival in a selected cohort of AML patients over 60 years.
Study details
Transplant Type : Allogeneic
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine